<DOC>
	<DOCNO>NCT02366663</DOCNO>
	<brief_summary>This randomized phase III trial study 90-yttrium ibritumomab tiuxetan combination chemotherapy compare combination chemotherapy alone stem cell transplant treat patient diffuse large b-cell non-Hodgkin lymphoma return period improvement . Radioactive substance link monoclonal antibody , 90-yttrium ibritumomab tiuxetan , bind cancer cell give radiation may help kill cancer cell . Drugs use chemotherapy , carmustine , etoposide phosphate , cytarabine , melphalan ( BEAM ) , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . It yet know whether 90-yttrium ibritumomab tiuxetan BEAM stem cell transplant effective BEAM alone treat patient diffuse large b-cell non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy 90-Yttrium Ibritumomab Tiuxetan Combination Chemotherapy Before Stem Cell Transplant Treating Patients With Relapsed Diffuse Large B-cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare overall survival ( OS ) two transplant arm , least two year follow-up . SECONDARY OBJECTIVES : I . To compare progression-free survival ( PFS ) , complete response ( CR ) partial response ( PR ) proportion day 100 , time hematopoietic recovery , incidence infection , grade III-IV toxicity , treatment-related mortality , incidence myelodysplastic syndrome ( MDS ) , secondary acute myelogenous leukemia ( AML ) . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive rituximab intravenously ( IV ) day -21 -14 , 90-yttrium ibritumomab tiuxetan IV day -14 . Patients also receive BEAM comprise carmustine IV 4 hour day -6 ; cytarabine IV 2 hour twice daily ( BID ) day -5 -2 ; etoposide IV 1 hour BID daily ( QD ) day -5 -2 ; melphalan IV day -1 . Patients undergo peripheral blood stem cell ( PBSC ) transplant day 0 . ARM II : Patients receive BEAM Arm I undergo PBSC transplant day 0 . After completion study treatment , patient follow weekly 30 day , 100 day , 6 month , 1 year , every 3 month 1 year , annually 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients CD20 positive diffuse large Bcell lymphoma confirm pathological biopsy report . 2 . Patients candidate autologous stemcell transplantation due primary refractory first relapse disease . 3 . Patients must chemosensitive disease achieve least partial response ( Cheson 2007 criterion ) last chemotherapy . 4 . Patients adequate autologous stem cell collection transplantation ( target &gt; = 2.5 x 10^6 CD34+ cells/kg ) . 5 . Patients must sign write informed consent . 6 . Adequate birth control fertile patient . 7 . All prior chemotherapy complete least three week study treatment . 8 . Marrow involvement le 25 % transplantation , limitation blood count ( low platelet count allow ) . 9 . Negative HIV antibody . 1 . Chemorefractory disease determine less partial response ( Cheson 2007 Criteria ) last chemotherapy . 2 . Two relapse initial response induction chemotherapy . 3 . Highgrade transformation earlier diagnosis lowgrade lymphoma . Patients `` De Novo '' Transformed DLBCL , define DLBCL lymph node biopsy discordant marrow paratrabecular small cell first diagnosis lymphoma , eligible adherent selection criterion . 4 . Bilirubin &gt; 3.0 mg/dl , transaminases &gt; 3 time upper normal limit . 5 . Creatinine &gt; 2.0 mg/dl . 6 . KPS &lt; 70 . 7 . Uncontrolled infection . 8 . Pregnancy lactation . 9 . Abnormal lung diffusion capacity ( DLCO &lt; 40 % predict ) . 10 . Severe cardiovascular disease ; New York Heart Association ( NYHA ) Functional Classification â‰¥2 . 11 . Active CNS disease involvement . 12 . Presence malignancy history prior malignancy within 5 year study entry . Within 5 year , patient treat Stage I II cancer eligible provided life expectancy &gt; 5 year relation prior malignance . The 5year exclusion rule apply tonon melanoma skin tumor situ cervical cancer . 13 . Pleural effusion ascites &gt; 1 liter . 14 . Known hypersensitivity rituximab . 15 . Psychiatric conditions/disease impair ability give inform consent adequately cooperate . 16 . Prior radioimmunotherapy . 17 . Prior autologous allogeneic HSCT . 18 . Active evidence Hepatitis B C infection ; Hepatitis B surface antigen positive . 19 . Patients prior radiation lung exclude study , although mediastinal irradiation permit minimal lung treatment volume . 20 . Patients receive &gt; 500cGy radiation kidney exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>autologous stem cell transplantation</keyword>
	<keyword>radioimmunotherapy</keyword>
	<keyword>Zevalin</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoma , Large B-Cell , Diffuse</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Lymphoma , B-Cell</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Immunologic Factors</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Physiological Effects Drugs</keyword>
</DOC>